

Erich M Sturgis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2907163/publications.pdf>

Version: 2024-02-01

198
papers

10,355
citations

50566

48
h-index

45040

94
g-index

201
all docs

201
docs citations

201
times ranked

12286
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. <i>Oral Diseases</i> , 2023, 29, 1565-1578.	1.5	9
2	Reconstructive Outcomes of Multilayered Closure of Large Skull Base Dural Defects Following Open Anterior Craniofacial Resection. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, 359-366.	0.4	1
3	Is 2045 Optimistic?â€”Concerns Regarding Rising Vaccine Hesitancy. <i>JAMA Oncology</i> , 2022, , .	3.4	0
4	Risk factors associated with patientâ€”reported fatigue among longâ€”term oropharyngeal carcinoma survivors. <i>Head and Neck</i> , 2022, 44, 952-963.	0.9	2
5	Detection accuracy of the Cobas HPV assay for highâ€”risk HPV in head and neck FNA biopsy specimens. <i>Cancer Cytopathology</i> , 2022, 130, 523-530.	1.4	2
6	Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. <i>Modern Pathology</i> , 2022, 35, 1045-1054.	2.9	16
7	Genetic variants in <i>CYP2B6</i> and <i>HSD17B12</i> associated with risk of squamous cell carcinoma of the head and neck. <i>International Journal of Cancer</i> , 2022, 151, 553-564.	2.3	7
8	Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression. <i>Head and Neck</i> , 2022, , .	0.9	0
9	Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Scientific Reports</i> , 2022, 12, 6662.	1.6	2
10	Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 751-761.	1.1	4
11	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	2.0	9
12	Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2021, 29, 97-105.	1.0	0
13	Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with oropharyngeal cancer treated with radiotherapy. <i>British Journal of Cancer</i> , 2021, 124, 628-633.	2.9	17
14	Bloodâ€”based biomarkers of human papillomavirusâ€”associated cancers: A systematic review and metaâ€”analysis. <i>Cancer</i> , 2021, 127, 850-864.	2.0	24
15	Conditional survival among patients with oropharyngeal cancer treated with radiation therapy and alive without recurrence 5 years after diagnosis. <i>Cancer</i> , 2021, 127, 1228-1237.	2.0	2
16	National trends in oropharyngeal cancer incidence and survival within the Veterans Affairs Health Care System. <i>Head and Neck</i> , 2021, 43, 108-115.	0.9	12
17	Free Flap Inset Techniques in Salvage Laryngopharyngectomy Repair: Impact on Fistula Formation and Function. <i>Laryngoscope</i> , 2021, 131, E875-E881.	1.1	14
18	An economic and disease transmission model of human papillomavirus and oropharyngeal cancer in Texas. <i>Scientific Reports</i> , 2021, 11, 1802.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Impact of provider type and number of providers on surveillance testing among survivors of head and neck cancers. <i>Cancer</i> , 2021, 127, 1699-1711.	2.0	3
20	Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening. <i>Journal of the American Society of Cytopathology</i> , 2021, 10, 399-405.	0.2	1
21	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 469.	1.2	9
22	Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. <i>International Journal of Particle Therapy</i> , 2021, 8, 234-247.	0.9	4
23	Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 615.	1.2	5
24	Determinants of patient-reported xerostomia among long-term oropharyngeal cancer survivors. <i>Cancer</i> , 2021, 127, 4470-4480.	2.0	14
25	Screening for HPV-related oropharyngeal, anal, and penile cancers in middle-aged men: Initial report from the HOUSTON clinical trial. <i>Oral Oncology</i> , 2021, 120, 105397.	0.8	11
26	Prevention and Screening of HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 297-308.	1.0	5
27	Surviving Surveillance—Are Current Head and Neck Cancer Posttreatment Surveillance Recommendations Better for Patients or Ourselves?. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, , .	1.2	1
28	Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients. <i>Laryngoscope</i> , 2020, 130, 1186-1194.	1.1	5
29	Knowledge matters and empowers: HPV vaccine advocacy among HPV-related cancer survivors. <i>Supportive Care in Cancer</i> , 2020, 28, 2407-2413.	1.0	9
30	Risks of Hypoparathyroidism After Total Thyroidectomy in Children: A 21-Year Experience in a High-Volume Cancer Center. <i>World Journal of Surgery</i> , 2020, 44, 442-451.	0.8	27
31	Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. <i>Radiotherapy and Oncology</i> , 2020, 142, 133-139.	0.3	21
32	Surveillance imaging for patients with head and neck cancer treated with definitive radiotherapy: A partially observed Markov decision process model. <i>Cancer</i> , 2020, 126, 749-756.	2.0	8
33	Patterns of Failure After Intensity Modulated Radiation Therapy in Head and Neck Squamous Cell Carcinoma of Unknown Primary: Implication of Elective Nodal and Mucosal Dose Coverage. <i>Advances in Radiation Oncology</i> , 2020, 5, 929-935.	0.6	8
34	Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. <i>JAMA Oncology</i> , 2020, 6, 1397.	3.4	183
35	CWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer. <i>Nature Communications</i> , 2020, 11, 3981.	5.8	86
36	Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. <i>British Journal of Cancer</i> , 2020, 123, 1456-1463.	2.9	65

#	ARTICLE	IF	CITATIONS
37	<sc>Highly conformal</sc> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. <i>Head and Neck</i> , 2020, 42, 3326-3335.	0.9	14
38	Lifetime health care costs of oropharyngeal cancer for commercially insured patients in the United States. <i>Head and Neck</i> , 2020, 42, 2321-2329.	0.9	0
39	Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 656.	1.2	13
40	Impact of a tobacco treatment program on abstinence and survival rates among current smokers with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 2440-2452.	0.9	7
41	Assessing thyroid cancer risk using polygenic risk scores. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 5997-6002.	3.3	39
42	Lymphopenia during radiotherapy in patients with oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 95-100.	0.3	18
43	Head and neck surgical oncology in the time of a pandemic: Subsite-specific triage guidelines during the <sc>COVID</sc>-19 pandemic. <i>Head and Neck</i> , 2020, 42, 1194-1201.	0.9	38
44	Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. <i>Radiotherapy and Oncology</i> , 2020, 148, 133-139.	0.3	11
45	Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. <i>Head and Neck</i> , 2020, 42, 1325-1328.	0.9	29
46	A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck. <i>Cancer Research</i> , 2020, 80, 2451-2460.	0.4	33
47	MicroRNA-Related Genetic Variants Associated with Survival of Head and Neck Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 127-136.	1.1	17
48	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in ^{V600E}-Mutated Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2019, 29, 1036-1043.	2.4	156
49	Direct medical cost of oropharyngeal cancer among patients insured by Medicaid in Texas. <i>Oral Oncology</i> , 2019, 96, 21-26.	0.8	3
50	A genetic variant within ³-UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 2276-2285.	1.3	5
51	Risk of second primary malignancies in head and neck cancer patients treated with definitive radiotherapy. <i>Npj Precision Oncology</i> , 2019, 3, 22.	2.3	31
52	Projected oropharyngeal carcinoma incidence among middle-aged US men. <i>Head and Neck</i> , 2019, 41, 3226-3234.	0.9	33
53	Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study. <i>Gynecologic Oncology</i> , 2019, 153, 266-270.	0.6	15
54	Lymphocyte telomere length predicts clinical outcomes of HPV-positive oropharyngeal cancer patients after definitive radiotherapy. <i>Carcinogenesis</i> , 2019, 40, 735-741.	1.3	5

#	ARTICLE	IF	CITATIONS
55	Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy. <i>Cancer</i> , 2019, 125, 1823-1829.	2.0	28
56	Incorporation of Cervista Human Papillomavirus 16/18 Assay Into Algorithms for Classifying Human Papillomavirus Status in Formalin-Fixed, Paraffin-Embedded Head and Neck Squamous Carcinoma Specimens. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 356-361.	1.2	0
57	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq1 1 0.784314 pgBT /OV 6.3 879	0.784314	879
58	Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes. <i>Cancer</i> , 2019, 125, 1536-1546.	2.0	19
59	Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 13-19.	0.9	7
60	Genetic Variants Predict Clinical Outcomes of HPV-Positive Oropharyngeal Cancer Patients after Definitive Radiotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 2225-2233.	3.2	20
61	A genetic variant at the miRNA187 binding site significantly modifies risk of HPV16-associated oropharyngeal cancer. <i>International Journal of Cancer</i> , 2018, 143, 1327-1334.	2.3	7
62	Outcomes of patients diagnosed with carcinoma metastatic to the neck from an unknown primary source and treated with intensity-modulated radiation therapy. <i>Cancer</i> , 2018, 124, 1415-1427.	2.0	18
63	Associations between expression levels of nucleotide excision repair proteins in lymphoblastoid cells and risk of squamous cell carcinoma of the head and neck. <i>Molecular Carcinogenesis</i> , 2018, 57, 784-793.	1.3	5
64	Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. <i>Head and Neck</i> , 2018, 40, 79-85.	0.9	25
65	Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. <i>Molecular Carcinogenesis</i> , 2018, 57, 361-369.	1.3	6
66	Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. <i>Radiotherapy and Oncology</i> , 2018, 126, 75-80.	0.3	19
67	Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 108.	1.2	49
68	Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature. <i>Human Pathology</i> , 2018, 76, 149-155.	1.1	11
69	Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. <i>Cancer</i> , 2018, 124, 960-965.	2.0	10
70	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3152-3161.	0.8	153
71	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 262-279.	1.8	160
72	Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With p16/HPV-Positive Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1029-1035.	0.4	18

#	ARTICLE	IF	CITATIONS
73	Reply to "Letter to the Editor in response to the article, "The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis" Oral Oncology, 2018, 86, 307.	0.8	0
74	Age-Structured Population Modeling of HPV-related Cervical Cancer in Texas and US. Scientific Reports, 2018, 8, 14346.	1.6	7
75	Myofibrosarcoma Mimicking a Vascular Thrombosis: A Case Report. Ultrasound International Open, 2018, 4, E136-E138.	0.3	0
76	Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid, 2018, 28, 982-990.	2.4	62
77	Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. , 2018, 6, 68.		148
78	Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Annals of Surgical Oncology, 2018, 25, 3380-3388.	0.7	46
79	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. Seminars in Radiation Oncology, 2018, 28, 108-113.	1.0	26
80	Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid, 2018, 28, 1301-1310.	2.4	96
81	Chronic hepatitis C virus infection in patients with nonoropharyngeal head and neck cancers. Oral Oncology, 2018, 85, 103-105.	0.8	2
82	The epidemiology of oral human papillomavirus infection in healthy populations: A systematic review and meta-analysis. Oral Oncology, 2018, 82, 91-99.	0.8	77
83	Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. European Journal of Cancer, 2017, 72, 166-176.	1.3	19
84	Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx. Scientific Reports, 2017, 7, 39765.	1.6	4
85	Symptom burden and dysphagia associated with osteoradionecrosis in long-term oropharynx cancer survivors: A cohort analysis. Oral Oncology, 2017, 66, 75-80.	0.8	26
86	A genome-wide association study yields five novel thyroid cancer risk loci. Nature Communications, 2017, 8, 14517.	5.8	117
87	Is there an increased risk of cancer among spouses of patients with an HPV-related cancer: A systematic review. Oral Oncology, 2017, 67, 138-145.	0.8	28
88	Radiation therapy for oropharyngeal squamous cell carcinoma: Executive summary of an ASTRO Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology, 2017, 7, 246-253.	1.1	73
89	Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx. Carcinogenesis, 2017, 38, 432-438.	1.3	6
90	Human Papillomavirus-Associated Oropharyngeal Cancer. JAMA Oncology, 2017, 3, 161.	3.4	2

#	ARTICLE	IF	CITATIONS
91	Medical Care Cost of Oropharyngeal Cancer among Texas Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1443-1449.	1.1	26
92	Diagnostic accuracy of serum antibodies to human papillomavirus type 16 early antigens in the detection of human papillomavirus-related oropharyngeal cancer. <i>Cancer</i> , 2017, 123, 4886-4894.	2.0	16
93	Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50. <i>Cancer</i> , 2017, 123, 3943-3954.	2.0	37
94	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. <i>Head and Neck</i> , 2017, 39, 2079-2087.	0.9	15
95	Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1244.	1.2	39
96	Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 28-35.	0.9	18
97	Genetic variants in microRNA-binding sites of DNA repair genes as predictors of recurrence in patients with squamous cell carcinoma of the oropharynx. <i>International Journal of Cancer</i> , 2017, 141, 1355-1364.	2.3	9
98	E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx. <i>Molecular Carcinogenesis</i> , 2017, 56, 1335-1343.	1.3	13
99	The national landscape of human papillomavirus-associated oropharynx squamous cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 504-512.	2.3	46
100	A functional variant at the miRNA binding site in <i>E2F1</i> gene is associated with risk and tumor HPV16 status of oropharynx squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , 2017, 56, 1100-1106.	1.3	12
101	Feeding Tube Utilization in Patients with Salivary Gland Malignancies. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 109-117.	1.1	1
102	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old. <i>Radiation Oncology</i> , 2017, 12, 150.	1.2	25
103	A functional variant at miRNA-122 binding site in <i>IL-1β</i> 3' UTR predicts risk of recurrence in patients with oropharyngeal cancer. <i>Oncotarget</i> , 2016, 7, 34472-34479.	0.8	8
104	Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 1702-1707.	2.0	17
105	Impact of selective neck dissection on chronic dysphagia after chemo-intensity-modulated radiotherapy for oropharyngeal carcinoma. <i>Head and Neck</i> , 2016, 38, 886-893.	0.9	10
106	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. <i>Cancer</i> , 2016, 122, 534-545.	2.0	62
107	Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. <i>Head and Neck</i> , 2016, 38, E1459-66.	0.9	28
108	Comparison of systemic therapies used concurrently with radiation for the treatment of human papillomavirus-associated oropharyngeal cancer. <i>Head and Neck</i> , 2016, 38, E1554-61.	0.9	11

#	ARTICLE	IF	CITATIONS
109	Improving patient outcomes through multidisciplinary treatment planning conference. <i>Head and Neck</i> , 2016, 38, E1820-5.	0.9	25
110	HPV vaccination in boys should not be discounted. <i>Lancet Public Health</i> , The, 2016, 1, e2-e3.	4.7	1
111	Osteoradionecrosis in patients with salivary gland malignancies. <i>Oral Oncology</i> , 2016, 57, 1-5.	0.8	9
112	Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. <i>Infectious Agents and Cancer</i> , 2016, 11, 21.	1.2	14
113	Selected single-nucleotide polymorphisms in <i>FOXE1</i> , <i>SERPINA5</i> , <i>FTO</i> , <i>EVPL</i> , <i>TICAM1</i> and <i>SCARB1</i> are associated with papillary and follicular thyroid cancer risk: replication study in a German population. <i>Carcinogenesis</i> , 2016, 37, 677-684.	1.3	34
114	Association Between Hepatitis C Virus and Head and Neck Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw035.	3.0	57
115	Expanding the benefits of HPV vaccination to boys and men. <i>Lancet</i> , The, 2016, 387, 1798-1799.	6.3	30
116	Effect of human papillomavirus seropositivity and <i>E2F2</i> promoter variants on risk of squamous cell carcinomas of oropharynx and oral cavity. <i>Carcinogenesis</i> , 2016, 37, 1070-1078.	1.3	5
117	Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer – A case matched analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 48-55.	0.3	177
118	Reply to radiotherapy for human papillomavirus–positive oropharyngeal cancers in the National Cancer Data Base. <i>Cancer</i> , 2016, 122, 3411-3412.	2.0	1
119	Human papillomavirus integration pattern and demographic, clinical, and survival characteristics of patients with oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1139-1144.	0.9	29
120	Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck. <i>BMC Cancer</i> , 2016, 16, 70.	1.1	2
121	Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. <i>Oral Oncology</i> , 2016, 56, 47-53.	0.8	88
122	Proposed Staging System for Patients With HPV-Related Oropharyngeal Cancer Based on Nasopharyngeal Cancer N Categories. <i>Journal of Clinical Oncology</i> , 2016, 34, 1848-1854.	0.8	64
123	Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 360-367.	0.4	88
124	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 440-451.	5.1	607
125	Reduced DNA double-strand break repair capacity and risk of squamous cell carcinoma of the head and neck – A case-control study. <i>DNA Repair</i> , 2016, 40, 18-26.	1.3	14
126	A variant at a potentially functional microRNA-binding site in <i>BRIP1</i> was associated with risk of squamous cell carcinoma of the head and neck. <i>Tumor Biology</i> , 2016, 37, 8057-8066.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Pre-miRNA variants as predictors of clinical outcome in patients with squamous cell carcinomas of the nonoropharynx. <i>Oncotarget</i> , 2016, 7, 26444-26453.	0.8	11
128	Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy. <i>Oncotarget</i> , 2016, 7, 35015-35025.	0.8	11
129	Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer. <i>Cancer</i> , 2015, 121, 3455-3464.	2.0	97
130	Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy. <i>International Journal of Cancer</i> , 2015, 137, 2454-2461.	2.3	14
131	HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status. <i>Oral Oncology</i> , 2015, 51, 662-667.	0.8	51
132	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. <i>Oral Oncology</i> , 2015, 51, 195-201.	0.8	13
133	A functional variant at miRNA-122 binding site in IL-1 β 3' UTR predicts risk and HPV-positive tumours of oropharyngeal cancer. <i>European Journal of Cancer</i> , 2015, 51, 1415-1423.	1.3	17
134	HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. <i>Clinical Cancer Research</i> , 2015, 21, 2861-2869.	3.2	59
135	Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior. <i>Oral Oncology</i> , 2015, 51, 832-838.	0.8	73
136	Risk factors for head and neck cancer in young adults: a pooled analysis in the INHANCE consortium. <i>International Journal of Epidemiology</i> , 2015, 44, 169-185.	0.9	128
137	Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study. <i>Radiotherapy and Oncology</i> , 2015, 117, 132-138.	0.3	21
138	Genetic Variants in DNA Double-Strand Break Repair Genes and Risk of Salivary Gland Carcinoma: A Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0128753.	1.1	4
139	Facial Nerve Paralysis due to a Pleomorphic Adenoma with the Imaging Characteristics of a Facial Nerve Schwannoma. <i>Journal of Neurological Surgery Reports</i> , 2014, 75, e84-e88.	0.3	14
140	Measuring the Extent of Total Thyroidectomy for Differentiated Thyroid Carcinoma Using Radioactive Iodine Imaging. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 410.	1.2	18
141	Epidemiology of HPV-associated oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 380-386.	0.8	388
142	Functional single nucleotide polymorphisms of the RASSF3 gene and susceptibility to squamous cell carcinoma of the head and neck. <i>European Journal of Cancer</i> , 2014, 50, 582-592.	1.3	8
143	Genetic Susceptibility to Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 38-48.	0.4	54
144	Low risk of second primary malignancies among never smokers with human papillomavirus-associated index oropharyngeal cancers. <i>Head and Neck</i> , 2013, 35, 794-799.	0.9	46

#	ARTICLE	IF	CITATIONS
145	An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center. <i>Cancer</i> , 2013, 119, 81-89.	2.0	145
146	Epidemiology of Oral-Cavity and Oropharyngeal Carcinomas. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, 507-520.	0.5	35
147	A Tale of Two Cancers: Carcinomas of the Oral Cavity and Oropharynx. <i>Otolaryngologic Clinics of North America</i> , 2013, 46, xiii-xvi.	0.5	0
148	International head and neck cancer epidemiology consortium: Update No. 9. <i>Head and Neck</i> , 2013, 35, 2-3.	0.9	2
149	Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. <i>Cancer</i> , 2013, 119, 2593-2601.	2.0	61
150	Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS6100-TPS6100.	0.8	1
151	Occurrence of familial malignant tumors in the first-degree relatives of patients with differentiated (non-medullar) thyroid carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1567-1567.	0.8	0
152	Relationship between level of lymph node metastasis (LNM) and survival in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 6087-6087.	0.8	0
153	International head and neck cancer epidemiology consortium: Update no. 8. <i>Head and Neck</i> , 2012, 34, 1817-1818.	0.9	0
154	Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. <i>Head and Neck</i> , 2012, 34, 1255-1262.	0.9	30
155	A comparison of the demographics, clinical features, and survival of patients with adenoid cystic carcinoma of major and minor salivary glands versus less common sites within the Surveillance, Epidemiology, and End Results registry. <i>Cancer</i> , 2012, 118, 3945-3953.	2.0	112
156	Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell Carcinoma. <i>Seminars in Radiation Oncology</i> , 2012, 22, 128-142.	1.0	225
157	Family history of cancer and risk of sporadic differentiated thyroid carcinoma. <i>Cancer</i> , 2012, 118, 1228-1235.	2.0	36
158	Adherence to head and neck cancer guidelines: Setting the stage for continual quality improvement.. <i>Journal of Clinical Oncology</i> , 2012, 30, 193-193.	0.8	0
159	Adherence to head and neck cancer guidelines: Multidisciplinary conference recommendations and care delivered.. <i>Journal of Clinical Oncology</i> , 2012, 30, 202-202.	0.8	1
160	Malignant fibrous histiocytoma of the head and neck region. <i>Head and Neck</i> , 2011, 33, 303-308.	0.9	27
161	The Epidemic of HPV-Associated Oropharyngeal Cancer Is Here: Is It Time to Change Our Treatment Paradigms?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 665-673.	2.3	178
162	Association of BRCA1 Single Nucleotide Polymorphisms with Risk of Differentiated Thyroid Carcinoma. <i>Laryngoscope</i> , 2011, 121, S110-S110.	1.1	0

#	ARTICLE	IF	CITATIONS
163	Differences in history of sexual behavior between patients with oropharyngeal squamous cell carcinoma and patients with squamous cell carcinoma at other head and neck sites. <i>Head and Neck</i> , 2011, 33, 847-855.	0.9	70
164	Human Papillomavirus Type 16 (HPV16) E6/E7-Specific Cytotoxic T Lymphocytes (CTLs) for Immunotherapy of HPV-Associated Malignancies. <i>Blood</i> , 2011, 118, 1913-1913.	0.6	0
165	Human papillomavirus and WHO type I nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2010, 120, 1990-1997.	1.1	70
166	Reduced DNA Repair Capacity for Removing Tobacco Carcinogen-Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics. <i>Clinical Cancer Research</i> , 2010, 16, 764-774.	3.2	50
167	Should Papillary Thyroid Carcinoma Be Observed?: A Word of Caution. <i>JAMA Otolaryngology</i> , 2010, 136, 444.	1.5	6
168	Liposarcoma of the head and neck: The University of Texas M. D. Anderson Cancer Center experience. <i>Head and Neck</i> , 2009, 31, 28-36.	0.9	66
169	Differentiated thyroid cancer associated with intestinal polyposis syndromes: A review. <i>Head and Neck</i> , 2009, 31, 1511-1519.	0.9	17
170	Sarcomas of the head and neck region. <i>Current Oncology Reports</i> , 2009, 11, 135-142.	1.8	48
171	Squamous cell carcinoma of the head and neck in never smoker-never drinkers: A descriptive epidemiologic study. <i>Head and Neck</i> , 2008, 30, 75-84.	0.9	161
172	<i>Fas</i> single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: A case-control analysis. <i>Head and Neck</i> , 2008, 30, 297-305.	0.9	16
173	Adenoid Cystic Carcinoma of the External Auditory Canal. <i>Laryngoscope</i> , 2008, 118, 1591-1596.	1.1	58
174	Alcohol Drinking in Never Users of Tobacco, Cigarette Smoking in Never Drinkers, and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. <i>Journal of the National Cancer Institute</i> , 2007, 99, 777-789.	3.0	837
175	Survival in patients with synovial sarcoma of the head and neck: Association with tumor location, size, and extension. <i>Head and Neck</i> , 2007, 29, 731-740.	0.9	135
176	Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007, 29, 682-699.	0.9	69
177	X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas. <i>Cancer</i> , 2007, 110, 318-325.	2.0	17
178	Trends in head and neck cancer incidence in relation to smoking prevalence. <i>Cancer</i> , 2007, 110, 1429-1435.	2.0	696
179	The role of human papillomavirus in squamous carcinoma of the head and neck. <i>Current Oncology Reports</i> , 2006, 8, 130-139.	1.8	34
180	After the Smoke Clears. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 96-103.	1.0	21

#	ARTICLE	IF	CITATIONS
181	RET Polymorphisms and Haplotypes and Risk of Differentiated Thyroid Cancer. <i>Laryngoscope</i> , 2005, 115, 1035-1041.	1.1	24
182	Radiation Response Genotype and Risk of Differentiated Thyroid Cancer: A Case-Control Analysis. <i>Laryngoscope</i> , 2005, 115, 938-945.	1.1	41
183	A pilot study of <i>Helicobacter pylori</i> infection and risk of laryngopharyngeal cancer. <i>Head and Neck</i> , 2005, 27, 22-27.	0.9	36
184	Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: A case series. <i>Head and Neck</i> , 2005, 27, 748-756.	0.9	23
185	Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: A case-control analysis. <i>International Journal of Cancer</i> , 2005, 115, 131-136.	2.3	50
186	Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: A review of molecular epidemiological studies. <i>Molecular Carcinogenesis</i> , 2005, 42, 65-92.	1.3	134
187	Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck. <i>Carcinogenesis</i> , 2004, 25, 1911-1916.	1.3	82
188	Descriptive epidemiology and risk factors for head and neck cancer. <i>Seminars in Oncology</i> , 2004, 31, 726-733.	0.8	184
189	Gamma radiation-induced apoptosis, G2 delay, and the risk of salivary and thyroid carcinomas? a preliminary report. <i>Head and Neck</i> , 2004, 26, 612-618.	0.9	10
190	A review of social and behavioral efforts at oral cancer preventions in India. <i>Head and Neck</i> , 2004, 26, 937-944.	0.9	20
191	Sarcomas of the head and neck region. <i>Current Opinion in Oncology</i> , 2003, 15, 239-252.	1.1	263
192	DNA Repair Gene ERCC1 and ERCC2/XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Otolaryngology</i> , 2002, 128, 1084.	1.5	108
193	Genetic susceptibility—molecular epidemiology of head and neck cancer. <i>Current Opinion in Oncology</i> , 2002, 14, 310-317.	1.1	82
194	XPD/ERCC2 EXON 8 Polymorphisms: rarity and lack of significance in risk of squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2002, 38, 475-477.	0.8	15
195	In vitro BPDE-induced DNA adducts in peripheral lymphocytes as a risk factor for squamous cell carcinoma of the head and neck. <i>International Journal of Cancer</i> , 2001, 93, 436-440.	2.3	38
196	Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. , 1999, 84, 220-224.		93
197	DNA repair and genomic instability in tobacco induced malignancies of the lung and upper aerodigestive tract. <i>Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews</i> , 1998, 16, 1-30.	2.9	8
198	Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. <i>Cancer Medicine</i> , 0, , .	1.3	3